These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1806438)

  • 1. Leukemic transformation in patients with 5Q- and additional abnormalities.
    Larripa I; Acevedo S; Palau Nagore MV; Bengiò R; Mondini N; Slavutsky I
    Haematologica; 1991; 76(5):363-7. PubMed ID: 1806438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
    Ghaddar HM; Stass SA; Pierce S; Estey EH
    Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes.
    Solé F; Prieto F; Badia L; Woessner S; Florensa L; Caballin MR; Coll MD; Besses C; Sans-Sabrafen J
    Cancer Genet Cytogenet; 1992 Nov; 64(1):12-20. PubMed ID: 1458444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
    Suciu S; Kuse R; Weh HJ; Hossfeld DK
    Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of megakaryocytic morphology in diagnosing 5q- syndrome.
    Thiede T; Engquist L; Billström R
    Eur J Haematol; 1988 Nov; 41(5):434-7. PubMed ID: 3208866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients.
    Pedersen B; Jensen IM
    Leukemia; 1991 Jul; 5(7):566-73. PubMed ID: 2072742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and cytogenetic features of 29 cases of myelodysplastic syndrome associated with del(20q)].
    Qin S; Liu SH; Bo LJ; Liu XP; Li CW; Dai Y; He GS; Shao ZH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Apr; 21(2):171-2. PubMed ID: 15079804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes.
    Stewart B; Verdugo M; Guthrie KA; Appelbaum F; Deeg HJ
    Br J Haematol; 2003 Dec; 123(5):879-85. PubMed ID: 14632779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
    Germing U; Lauseker M; Hildebrandt B; Symeonidis A; Cermak J; Fenaux P; Kelaidi C; Pfeilstöcker M; Nösslinger T; Sekeres M; Maciejewski J; Haase D; Schanz J; Seymour J; Kenealy M; Weide R; Lübbert M; Platzbecker U; Valent P; Götze K; Stauder R; Blum S; Kreuzer KA; Schlenk R; Ganser A; Hofmann WK; Aul C; Krieger O; Kündgen A; Haas R; Hasford J; Giagounidis A
    Leukemia; 2012 Jun; 26(6):1286-92. PubMed ID: 22289990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.
    Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
    Leukemia; 1993 Apr; 7(4):499-508. PubMed ID: 8464227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
    Lewis S; Oscier D; Boultwood J; Ross F; Fitchett M; Rack K; Abrahamson G; Buckle V; Wainscoat JS
    Am J Hematol; 1995 Jul; 49(3):194-200. PubMed ID: 7604812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The bone marrow karyotype in refractory anemia and preleukemia].
    Bernard P; Vagner-Capodano AM; Stahl A; Broustet A; Boisseau MR; Ayraud N
    Pathol Biol (Paris); 1982 Nov; 30(9):798-801. PubMed ID: 6760084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.